Company: Rigel Pharmaceuticals [1]
Starting stock price: $11.89
Ending stock price: $25.39
Percent Change: 113.54%
Details: Rigel has a number of drug candidates in its pipeline. R788 is in Phase II trials for rheumatoid arthritis, ITP and B-cell lymphoma. It's also partnering with Merck Serono on the Phase II compound R763 for solid tumors and leukemia. Additionally, Rigel and Pfizer are developing R343 for asthma.
More News:
Merck Serono exercises option to Rigel's R763. Report [2]
Serono seals oncology drug pact with Rigel. Report [3]
Links:
[1] http://www.rigel.com/indexnoflash.php
[2] http://www.fiercepharma.com/press-releases/press-release-merck-serono-exercises-option-rigels-r763-as703569-and-aurora-kinase-in
[3] http://www.fiercepharma.com/story/serono-seals-oncology-drug-pact-with-rigel/2005-10-25
[4] http://www.fiercepharma.com/special-reports/sgx-pharmaceuticals-best-pharma-stocks-2007
[5] http://www.fiercepharma.com/special-reports/best-pharma-stocks-2007